Graham Capital Management’s CRISPR Therapeutics CRSP Stock Holding History

Graham Capital Management’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-4,358	Closed	-$205K	–	1275
2024 Q3	$205K	Sell	4,358 -951	-18%	-$48.3K	﹤0.01%	904
2024 Q2	$287K	Buy	+5,309	New	+$307K	0.01%	754
2023 Q3	–	Sell	-6,921	Closed	-$389K	–	1054
2023 Q2	$389K	Buy	+6,921	New	+$393K	0.01%	617
2022 Q3	–	Sell	-10,667	Closed	-$648K	–	1102
2022 Q2	$648K	Buy	10,667 +6,239	+141%	+$367K	0.03%	582
2022 Q1	$277K	Buy	+4,428	New	+$278K	0.01%	751

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Graham Capital Management's CRSP Position: Q4 2024 in Review

Graham Capital Management sold out of CRISPR Therapeutics (CRSP) in Q4 2024, closing a stake of 4,358 shares — an estimated $205K sold.

Graham Capital Management first reported a position in CRSP in Q1 2022 and held it in 5 quarters. The position peaked at $648K in Q2 2022. 404 funds tracked by Wall St. Rank hold CRSP as of Q4 2024.

Graham Capital Management reported no remaining CRISPR Therapeutics position as of Q4 2024 after selling out during the quarter.
Graham Capital Management sold 4,358 CRISPR Therapeutics shares in Q4 2024, an estimated $205K.
Graham Capital Management first reported a position in CRISPR Therapeutics in Q1 2022 and held it in 5 quarters.
Graham Capital Management's CRISPR Therapeutics position peaked at $648K in Q2 2022.
404 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2024.

Based on Graham Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.